New gene therapy for cystic fibrosis to undergo Phase II testing in the UK
This article was originally published in Scrip
Executive Summary
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is undertaking what it says is the largest Phase II study of its kind, investigating a new gene therapy, (GL67A/pGM169), in 130 cystic fibrosis (CF) patients aged 12 years and over.